A Diagnostic Leader in personalized onco-medicine

Providing High-Quality Gene Expression Prognostic & Predictive Services for the Personalized Medicine
arena to Enable Better Management of Cancer Patients

Company

Business Consultants

David Fink, MBA
David Fink has 30 years of pharmaceutical experience specializing in building new businesses or conducting business turnarounds. Most recently, he was SVP and Corporate Officer of Nycomed US ($800 million annual sales) and General Manager of Pharma Derm ($300 million derm specialty company). Previously, he was SVP, Commercial Operations and a Corporate Officer at Savient Pharmaceuticals. Prior to that, David was at MedPointe Pharmaceuticals where he was on the management committee, an equity investor and Vice President, Marketing and Lifecycle Management. In “big pharma”, David was Vice President at Bristol Myers Squibb where he led the U.S. HIV/Immunology franchise to exceed $600 million in annual sales. He also started the anti-infective business at Schering where in addition to building that new business from scratch, he led & expanded the Dermatology business and initiated development of a CNS portfolio.
Mr. Fink has successfully launched over a dozen new products and indications, re-launched ten marketed products, and initiated pre-launch development and commercialization efforts for numerous other products. He has spanned a variety of therapeutic categories including allergy, anti-infectives, cardiology, central nervous system, dermatology, rheumatology and supportive oncology. David has built six marketing organizations, seven sales organizations, and led numerous strategic alliances with partners including AstraZeneca, Bausch & Lomb, Ferring, Gillette, Leo Pharmaceuticals, Medigene, Reckitt, and Sepracor.
David received his MBA from the University of Wisconsin – Milwaukee and his undergraduate degree from Radford University.

Dr. Victor Sloan, M.D.
Currently, Dr. Sloan is VP and Head of the Immunology Practice at UCB Pharma, where he oversees full development activities for the company’s immunology portfolio. He has almost 20 years of experience in all phases of drug development at various companies including Merck & Co., Novartis Pharmaceuticals and Celgene Corporation. Dr. Sloan received his AB from the University of Chicago and his MD from New York Medical College. He completed a research residency in internal medicine at Montefiore Medical Center and his fellowship in rheumatology at the University of California San Francisco and Robert Wood Johnson Medical School. He is a Fellow of the American College of Physicians and a Fellow of the American College of Rheumatology. Dr. Sloan is a board-certified rheumatologist and holds an appointment as Clinical Associate Professor in the Division of Rheumatology and Connective Tissue Diseases at the Rutgers RobertWood Johnson Medical School where he continues to see patients on a volunteer basis.
Dr. Sloan is a member of the Board of Directors of the Arthritis Foundation, New Jersey Chapter and the Lupus Foundation of America, New Jersey Chapter.

Harun Sevimli, MBA
Director, International Business Development

Mr. Sevimli has extensive experience in international trade, consulting, financing, and marketing. He is multi national and multi lingual. He has owned companies in Germany, Turkey and in the U.S. and handled logistics for WFP/U.N. for the Food Bank in Northern Iraq. His latest company, Amerturk, Inc, a full service asset management partner for electronics retailers and wholesalers includes several Fortune 500 companies for customers. Mr. Sevimli brings his skills in international trade to the Consumer Genetics product line. He has helped to established partners in more than 33 countries since the end of 2008. Mr. Sevimli has a degree in finance.